Abstract:
There are provided a plasma display device in which dark contrast can be enhanced without deteriorating an image quality and a method of driving a plasma display panel. In a case of driving a plasma display device in which a magnesium oxide layer containing a magnesium oxide crystal to be excited by the irradiation of an electron beam and performing a cathode luminescence having a peak in a wavelength range of 200 to 300 nm by a sub-field method, in order to initialize all display cells, reset discharge is caused in each of the display cells in M sub-fields of N consecutive sub-fields (0
Abstract:
A plasma display device having a plasma display panel in which, each display cell contains a magnesium oxide layer including magnesium oxide crystals that are excited by an electron beam to emit cathode luminescence light having a peak in a wavelength range of 200 to 300 nm. In an addressing period, a row electrode driving circuit applies a scanning pulse to one row electrodes of row electrode pairs in turn, while a column electrode driving circuit supplies column electrodes with data pulses corresponding to one row electrode which is applied with the scanning pulse.
Abstract:
A plasma display panel has a front glass substrate and a back glass substrate facing each other on either side of a discharge space, row electrode pairs formed on the rear-facing face of the front glass substrate, and a dielectric layer covering the row electrode pairs. Discharge cells are formed in the discharge space. The PDP further has crystalline MgO layers each provided on a part of portion of the face of the front glass substrate having the row electrode pairs formed thereon and facing toward the discharge space. The crystalline MgO layers include magnesium oxide crystals causing a cathode-luminescence emission having a peak within a wavelength range of 200 nm to 300 nm upon excitation by an electron beam.
Abstract:
The present invention relates to a novel channel structure of human amyloid beta protein (AbP) in lipid membranes and a rapid, quantitative and specific assay for screening test compounds, such as drugs, ligands (natural or synthetic), proteins, peptides and small organic molecules for their ability to bind and block the membrane AbP channels. The invention further relates to screening and identifying therapeutically relevant compounds for treating Alzheimer's disease and other disorders.
Abstract:
There are provided a plasma display device in which dark contrast can be enhanced without deteriorating an image quality and a method of driving a plasma display panel. In a case of driving a plasma display device in which a magnesium oxide layer containing a magnesium oxide crystal to be excited by the irradiation of an electron beam and performing a cathode luminescence having a peak in a wavelength range of 200 to 300 nm by a sub-field method, in order to initialize all display cells, reset discharge is caused in each of the display cells in M sub-fields of N consecutive sub-fields (0